PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. (June 2017) - Blakemore, S.J.; Daigle, S.R.; McDonald, A.A.; Morschhauser, F.; Ribrag, V.; Salles, G.; McKay, P.; Tilly, H.; Schmitt, A.; Le Gouill, S.; Fruchart, C.; Radford, J.; et al.